GlassScriptPhysician profile
Shae W Steward
NPI 1275979734
$809.14
in general payments reported to CMS, 2019-2025
17 companies · $159 in 2025
The $159 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $146 · 2020: $40.12 · 2021: $37.75 · 2022: $71.48 · 2023: $191 · 2024: $164 · 2025: $159.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $513.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $513.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $171.88 | 2020-2023 | Lensx |
| Alexion Pharmaceuticals, INC. | $122.26 | 2023-2025 | Ultomiris, Soliris |
| Apellis Pharmaceuticals, INC. | $90.09 | 2023-2025 | Syfovre |
| Kala Pharmaceuticals, INC. | $65.00 | 2019-2020 | |
| Ocular Therapeutix, INC. | $52.88 | 2024-2025 | Dextenza |
| Johnson & Johnson Surgical Vision, INC. | $51.85 | 2019 | |
| Sight Sciences, INC. | $48.34 | 2024 | Omni Surgical System |
| Abbvie INC. | $38.46 | 2023-2025 | Durysta |
| Omeros Corporation | $32.92 | 2019 | |
| Catalyst Pharmaceuticals, INC. | $25.00 | 2023 | Firdapse |
| Bausch & Lomb Americas INC. | $17.83 | 2025 | Envista Mx60 Iol, Scoutpro Osmolarity System |
| Astellas Pharma US INC | $17.81 | 2025 | Izervay |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $17.60 | 2019 | |
| Rxsight INC | $17.56 | 2022 | |
| Ani Pharmaceuticals, INC. | $14.66 | 2025 | Iluvien |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Travere Therapeutics, INC. | $12.69 | 2022 | |
| Allergan, INC. | $12.31 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shae Steward listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.